Erytop-N Gel is a topical formulation containing Clindamycin 1% w/w and Nicotinamide 4% w/w, indicated for the treatment of inflammatory acne vulgaris. Clindamycin, a lincosamide antibiotic, exerts its therapeutic effect by inhibiting bacterial protein synthesis, thereby reducing the proliferation of Propionibacterium acnes, a key pathogen implicated in acne pathogenesis. Nicotinamide, a form of vitamin B3, possesses anti-inflammatory and sebostatic properties, contributing to the reduction of erythema and lesion count while improving skin barrier function. The combination of these active ingredients provides a dual mechanism of action targeting both bacterial colonization and inflammatory responses. Erytop-N Gel is recommended for topical application once or twice daily on affected areas, ensuring skin is clean and dry prior to use. Patients should avoid contact with eyes, mucous membranes, and broken skin. Common adverse effects may include mild irritation, dryness, or erythema at the application site, which typically resolve with continued use. Caution is advised in individuals with known hypersensitivity to clindamycin or nicotinamide. This product is not intended for systemic infections and should be used under medical supervision as part of a comprehensive acne management plan.